Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (470)	12/6/2004 1:26:10 AM
From: zeta1961	Read Replies (1) \| Respond to of 887

<<Anyone well versed in MDS care to comment on the playing field right now?>> Not well versed but somewhat familiar. I'm starting here... Message 20829517 Above link to PHRM's AzaC label which got them the first approved drug for MDS(also orphan)..confusing, imo..SUPG is pushing dacugen along with the help of MOGN(thanks to Erik for that info) What I find quite striking is that dacugen data, AzaC, and now what I see of ATO, that the high risk patients seem to have a sound response.. I'll try to do some digging to provide for your evaluation<g> Zeta